Literature DB >> 16140736

Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.

Florent C Bender1, J Charles Whitbeck, Huan Lou, Gary H Cohen, Roselyn J Eisenberg.   

Abstract

Virion glycoproteins gB, gD, and gH/gL play essential roles for herpes simplex virus (HSV) entry. The function of gD is to interact with a cognate receptor, and soluble forms of gD block HSV entry by tying up cell surface receptors. Both gB and the nonessential gC interact with cell surface heparan sulfate proteoglycan (HSPG), promoting viral attachment. However, cells deficient in proteoglycan synthesis can still be infected by HSV. This suggests another function for gB. We found that a soluble truncated form of gB bound saturably to the surface of Vero, A431, HeLa, and BSC-1 cells, L-cells, and a mouse melanoma cell line expressing the gD receptor nectin-1. The HSPG analog heparin completely blocked attachment of the gC ectodomain to Vero cells. In contrast, heparin only partially blocked attachment of soluble gB, leaving 20% of the input gB still bound even at high concentrations of inhibitor. Moreover, heparin treatment removed soluble gC but not gB from the cell surface. These data suggest that a portion of gB binds to cells independently of HSPG. In addition, gB bound to two HSPG-deficient cell lines derived from L-cells. Gro2C cells are deficient in HSPG, and Sog9 cells are deficient in HSPG, as well as chondroitin sulfate proteoglycan (CSPG). To identify particular gB epitopes responsible for HSPG-independent binding, we used a panel of monoclonal antibodies (MAbs) to gB to block gB binding. Only those gB MAbs that neutralized virus blocked binding of soluble gB to the cells. HSV entry into Gro2C and Sog9 cells was reduced but still detectable relative to the parental L-cells, as previously reported. Importantly, entry into Gro2C cells was blocked by purified forms of either the gD or gB ectodomain. On a molar basis, the extent of inhibition by gB was similar to that seen with gD. Together, these results suggest that soluble gB binds specifically to the surface of different cell types independently of HSPG and CSPG and that by doing so, the protein inhibits entry. The results provide evidence for the existence of a cellular entry receptor for gB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140736      PMCID: PMC1212636          DOI: 10.1128/JVI.79.18.11588-11597.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting.

Authors:  G H Cohen; V J Isola; J Kuhns; P W Berman; R J Eisenberg
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

2.  Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants.

Authors:  P E Pellett; K G Kousoulas; L Pereira; B Roizman
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1.

Authors:  C G Miller; C Krummenacher; R J Eisenberg; G H Cohen; N W Fraser
Journal:  Mol Ther       Date:  2001-02       Impact factor: 11.454

4.  Characterization of cell-cell fusion mediated by herpes simplex virus 2 glycoproteins gB, gD, gH and gL in transfected cells.

Authors:  Martin I Muggeridge
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

Review 5.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

6.  Oligomerization of herpes simplex virus glycoprotein B.

Authors:  L Claesson-Welsh; P G Spear
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Plasma membrane requirements for cell fusion induced by herpes simplex virus type 1 glycoproteins gB, gD, gH and gL.

Authors:  Helena Browne; Birgitte Bruun; Tony Minson
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

8.  Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate.

Authors:  E Trybala; J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate.

Authors:  P E Pertel; A Fridberg; M L Parish; P G Spear
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

10.  Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Authors:  T C Holland; S D Marlin; M Levine; J Glorioso
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

View more
  78 in total

1.  Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

Authors:  Hyunjung Baek; Hiroaki Uchida; Kyungok Jun; Jae-Hong Kim; Masahide Kuroki; Justus B Cohen; Joseph C Glorioso; Heechung Kwon
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB.

Authors:  Doina Atanasiu; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

3.  Stable association of herpes simplex virus with target membranes is triggered by low pH in the presence of the gD receptor, HVEM.

Authors:  J Charles Whitbeck; Yi Zuo; Richard S B Milne; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

5.  Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops.

Authors:  Brian P Hannah; Tina M Cairns; Florent C Bender; J Charles Whitbeck; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

6.  Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition.

Authors:  Hiroaki Uchida; Waris A Shah; Ali Ozuer; Arthur R Frampton; William F Goins; Paola Grandi; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

7.  Dual split protein-based fusion assay reveals that mutations to herpes simplex virus (HSV) glycoprotein gB alter the kinetics of cell-cell fusion induced by HSV entry glycoproteins.

Authors:  Doina Atanasiu; Wan Ting Saw; John R Gallagher; Brian P Hannah; Zene Matsuda; J Charles Whitbeck; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2013-08-14       Impact factor: 5.103

8.  Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans.

Authors:  Adam L Vanarsdall; Brent J Ryckman; Marie C Chase; David C Johnson
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Role of the UL45 protein in herpes simplex virus entry via low pH-dependent endocytosis and its relationship to the conformation and function of glycoprotein B.

Authors:  Stephen J Dollery; Kristin D Lane; Mark G Delboy; Devin G Roller; Anthony V Nicola
Journal:  Virus Res       Date:  2010-01-18       Impact factor: 3.303

10.  Glycoprotein D actively induces rapid internalization of two nectin-1 isoforms during herpes simplex virus entry.

Authors:  Katie M Stiles; Claude Krummenacher
Journal:  Virology       Date:  2010-01-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.